Vaxcyte Inc

• Country

  United States of America

• Sector

  Health Care

• Industry group

  Pharmaceuticals, Biotechnology & Life Sciences

• Industry

  Biotechnology

• Sub-sector

  Health Care

• Capitalization (millions of $)

  6708.2

• Ticker

  PCVX.O

• ISIN

  US92243G1085

• IPO date

  2020-06-12

• Availability on Russian exchanges

  Yes

• Reporting for

  2024-02-27

• Date fact. publication of reports

  2023-12-31

Vaxcyte Inc. is a vaccine company, which is focused on developing vaccines designed to prevent or treat common and deadly infectious diseases worldwide. Its cell-free protein synthesis platform enables it to design and produce protein carriers and antigens. Its pipeline includes VAX-24, VAX-XP, VAX-A1 and VAX-PG. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine (PCV). The Company's second PCV candidate, VAX-XP, uses its modular platform and builds on the technical proof of concept established by VAX-24. VAX-A1 is a conjugate vaccine being developed for group A strep infections. Its VAX -PG is being developed as a protein vaccine for the treatment of periodontitis.